MD Anderson, Oncora Medical team up to fight cancer with precision medicine alliance

Collaborative team will combine tools for collection and prediction of oncology outcomes to enable precision radiation oncology

, a precision radiation oncology software company, and Âé¶¹Ó³»­ MD Anderson Cancer Center, today announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.

During Phase I, MD Anderson oncologists and information technology professionals will work with Oncora¡¯s team of data scientists and engineers to install Oncora¡¯s Precision Radiation Oncology Platform, a software system built to assist radiation oncologists in the development of personalized treatment plans based on outcome predictions. Oncora¡¯s platform will be fueled by data from MD Anderson¡¯s electronic medical record system, tumor registry, radiation therapy planning system, and Brocade, an innovative software product developed by MD Anderson in 2014. Brocade was developed by , associate professor of Radiation Oncology, and author of a published in the April 2016 issue of the Journal of the American College of Radiology that demonstrated a 70 percent reduction in the time physicians spend documenting clinical data using Brocade.

Brocade, a web-based clinical documentation tool used by MD Anderson radiation oncologists, enables intuitive collection of structured data about patient diagnosis, treatment and radiation side effects, and generates narrative-style clinical documentation for medical records. 

Oncora will engineer complete interoperability between their Precision Radiation Oncology Platform and Brocade to explore the potential value of a combined product.

¡°This partnership provides an opportunity for precision medicine to truly improve the way cancer treatments are designed and delivered,¡± said Oncora Medical co-founder and CEO, David Lindsay. ¡°We¡¯re excited to work with MD Anderson in an effort to improve care for patients.¡±

Precision medicine ¨C delivering the best treatment to the right patient at the optimal time ¨C could improve cancer survival rates while minimizing unintended side effects. Tools for collecting quality clinical data and predicting specific radiation treatment outcomes are necessary to make precision medicine a reality.

¡°We believe this partnership could be a significant step forward for the field of radiation oncology and our patients,¡± said Smith. ¡°Through this alliance, we hope to improve workflows and processes for radiation oncologists and simultaneously give radiation oncologists access to better information to support real-time, precision medical decision making.¡±